Molecular Targets 2021: The Latest Efforts to Overcome Resistance to KRAS Inhibitors
Once considered undruggable, mutant KRAS has emerged in recent years as a viable target for anticancer therapeutics. As a...
Once considered undruggable, mutant KRAS has emerged in recent years as a viable target for anticancer therapeutics. As a...
After three decades of failed efforts to target the elusive KRAS and its family members NRAS and HRAS, proto-oncogenes...